ClinicalTrials.gg
RecruitingNCT06460012STELLA-RUpdated Oct 23, 2025

Support Via Technology: Living and Learning With Advancing Dementia-REVISED

An interventional study of STELLA-R Curriculum and Unrestricted Access in Caregiver Burden, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 228 studies in Caregiver Burden with a site in United States — 59 open to participants now, 71 under way, 1 of them phase 3. Caregiver Burden · United States.

Planned enrollment
32nd of 208
238 · median 60
Started
2024
with 24 others
No phase
190 of 228
50 open now
Primary completion
2026-12
later than 15 of 70 live
Registered
166th of 228
by date
Lead sponsor
5 of 228
Oregon Health and Science University

Among the 228 studies in Caregiver Burden with a site in United States, this one is the 32nd largest by planned enrollment of the 208 interventional ones that give a count, is one of 25 that started in 2024, is one of 190 with no phase, reaches primary completion later than 15 of the 70 other live ones, and was the 166th registered.

Caregiver Burden

503 studies on the registry are indexed under Caregiver Burden; 166 are open to participants now.

Browse Caregiver Burden studies →

Open to participants now

59 of the 228 studies in Caregiver Burden with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Caregiver Burden studies recruiting now, 69 (77%) set no upper age limit and 7 (8%) stop at 75 or younger; 8 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Caregiver Burden with a site in United States, or all of them as a file.
02

Study summary

STELLA-R is a multicomponent, self-directed, online intervention designed to facilitate effective management of behavioral and psychological symptoms that are common in many types of dementia. The curriculum instructs care partners to use the ABC approach, a cognitive behavioral technique that teaches care partners to describe a Behavior, then consider the Activators and Consequences of a care recipient behavior. The goal of this intervention is to reduce care partner burden and decrease reactivity to upsetting behaviors.

Read the detailed description

Providing care for a family member with Alzheimer's disease and related dementias (ADRD, aka, "dementia") is both rewarding and risky. Care partners exposed to chronic stress, often over years, are susceptible to physical and psychological ailments. Dementia involves neurodegeneration and those affected typically depend on family members for support and physical care. The "care partners" for those with dementia often experience concerning psychological and physical outcomes due to the demands of caregiving. No matter what type of dementia, most care partners experience some burden. The burden is often related to the behavioral symptoms that most people with dementia experience.

Care partners for those with dementia experience burden, grief, exhaustion and physical ailments. Programs for these care partners are more available. Effective interventions that reduce care partner burden and health risks are also available, but various factors impede participation, including distance, cost, behavioral symptoms of dementia, stigma and social anxiety. Recognizing the need to reduce barriers to access, scientists have turned to internet-based interventions.

The STELLA suite of research studies addresses the need for easily accessible, effective interventions designed to reduce burden in care partners for those with dementia. These studies examine the acceptability, feasibility, and efficacy of interventions modeled on Teri's psychoeducational behavior change intervention. We have completed two pilot studies for care partners for those with dementia using interventions with the STELLA-R precursor. These studies found early efficacy and acceptability for the intervention. We are currently testing a STELLA intervention which uses objective, technology-based assessments (OHSU IRB # 19306) and another, larger study which tests a STELLA intervention with a large national sample (OHSU IRB # 22288; NIA R01AG067546). In addition, with funding from the Association for Frontotemporal Degeneration (AFTD) we tested a similar intervention (STELLA-FTD) for care partners caring for a family member with frontotemporal dementia (OHSU IRB # 22721).

In all STELLA studies care partners work with professional guides to use the ABC analytic approach to describe a distressing behavior, then identify its activators and consequences. With this information, care partners can develop plans to reduce behavioral symptoms. In this proposed study, we will assess an online version of Tele-STELLA.

STELLA-R is informed by the World Health Organization (WHO) guidance to include rehabilitation science in dementia care to facilitate effective management of the advancing behavioral, communication, physical and social changes that come with progressive neurodegenerative dementias (e.g., Alzheimer's disease, frontotemporal degeneration, Lewy Body dementia). Grounded in self-efficacy theory and foundational research, STELLA-R will train care partners to address current behavioral symptoms and prepare for future ones.

The specific aims of this study are:

Aim 1. Assess feasibility and acceptability of STELLA-R

Aim 2. Compare the efficacy of STELLA-R in reducing care partner reactivity to dementia-related behavioral symptoms between two groups.

03

Conditions studied

  • Caregiver Burden

Keywords

  • caregivers
  • dementia
  • RMBPC
  • caregiver support
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult caring for family member with ADRD
  • Age of 18 years or older
  • Speaks and understands English to be able to participate in intervention
  • Owns a telephone (smartphone, cell phone or landline)
  • Has email and mailing address to receive study materials and surveys
  • Provides to participate in the research
  • Lives in Oregon, Washington or Idaho
  • Identifies two or more behavioral symptoms that are distressing to them (care partner)

Exclusion criteria

Exclusion Criteria:

  • Vision problems severe enough to prevent participation
  • Unwilling or unable to adequately follow study instructions and participate in study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
238 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Care partners start the STELLA-R Curriculum immediately after enrollment.

    Behavioral: STELLA-R Curriculum · Behavioral: Unrestricted Access · Behavioral: Limited Access

  • Active comparator
    Waitlist Control Group

    Care partners start the STELLA-R Curriculum 8 weeks after enrollment.

    Behavioral: STELLA-R Curriculum · Behavioral: Unrestricted Access · Behavioral: Limited Access

Interventions

  • BehavioralSTELLA-R Curriculum

    The STELLA-R curriculum is presented utilizing the ABC analytic approach to address care recipient's distressing behaviors. Using the scaffold of the ABC pyramid, they will receive video instructions on how to fully define the Behaviors they want to address by observing, describing, and writing about them. The care partners will learn to identify the Activators, the triggers for the behaviors. Next, care partners will learn to consider what happens after the behaviors, the Consequences. This is an 8-week self-directed, online weekly curriculum.

  • BehavioralUnrestricted Access

    Following the STELLA-R curriculum, care partners will receive 8 weeks of unrestricted access to all lessons and resources.

    Also known as: Post-Intervention Phase, Review Phase

  • BehavioralLimited Access

    Experimental and Waitlist Control group will experience 8 consecutive weeks of limited access to the STELLA-R website and resources. Waitlist Control will experience this from Week 1 to Week 8 while the Experimental Group will reach this phase from Week 17 to Week 24.

    Also known as: Restricted Access

06

What researchers measure

Primary outcomes

  1. Revised Memory and Behavior Problems Checklist (RMBPC)

    The primary outcome variable, reactivity, will be assessed with the RMBPC, which measures the frequency of care recipient behavioral symptoms and care partner reactions to these behaviors. The RMBPC was chosen because it aligns with our theoretical foundation that assumes burden is a result of care partner reactions to behavioral symptoms. The RMBPC is a 29-item caregiver report measure, 5-point Likert scale with frequency measuring from 0 (never occurred) to 4 (daily or more often) and reactivity measuring from 0 (not at all) to 4 (extremely) for a total score between 0-116 for each subscale (frequency subscale and reactivity subscale). Higher scores indicate greater behavioral problems.

    Time frame: Week 1, Week 8, Week 16, Week 24

  2. Feasibility of STELLA-R Intervention

    We will assess the feasibility of implementing STELLA-R across Oregon, Washington and Idaho. We will analyze metadata from the STELLA-R website to assess care partner usage of intervention materials. We will assess data from the surveys to characterize the sample, assess program acceptability, and measure treatment fidelity. We will compare demographic information, computer use, health-care usage, behavioral symptom frequency, medication use, care partner reactivity, burden and depression.

    Time frame: 10 months

  3. Acceptability of STELLA-R Intervention

    For acceptability, we will utilize the STELLA-R Experience Survey which is a 16-item survey on satisfaction, privacy, and ease of use. We will analyze the STELLA-R Experience Survey results using descriptive statistics. We will identify themes of acceptance, or lack thereof, of STELLA-R and the underpinnings of their impressions.

    Time frame: Week 24

Secondary outcomes

  1. Fortinsky's Measurement of Family Care Partner Self-Efficacy for Managing Dementia

    Self-efficacy, the mediating variable, will be assessed using Fortinsky's measurement of family care partner self-efficacy for managing dementia. Fortinsky's assess the targets in STELLA-R: behavior symptom management and service use. Fortinsky's measurement is a 9-item Likert scale ranging from 1 (not at all certain) to 10 (very certain). Higher scores are associated with fewer depressive symptoms and fewer physical health symptoms.

    Time frame: Week 1, Week 8, Week 16, Week 24

  2. Preparedness for Caregiving Scale

    The Preparedness for Caregiving Scale is a 10-item Likert scale ranging from 0 (not at all prepared) to 4 (very well prepared). We will measure care partner preparedness for current and future challenges to test the effect of a group-based intervention.

    Time frame: Week 1, Week 8, Week 16, Week 24

  3. Ten-Item Personality Inventory (TIPI)

    The Ten-Item Personality Inventory is a 10-item Likert scale measure to assess introversion and extraversion. Choices range from 1 (disagree strongly) to 7 (agree strongly) with reverse scoring on items 2, 4, 6, 8 and 10. Scoring on items are as follows: extraversion: 1, 6R; agreeableness: 2R, 7; conscientiousness: 3, 8R; emotional stability: 4R, 9; openness to experiences: 5, 10R. We will use this measure to test the effect of a group-based intervention.

    Time frame: Week 1

  4. Personalized Target Behavior Survey

    The Personalized Target Behavior Survey measure frequency and reactivity of up to 3 personalized behaviors identified by care partners. We will collect data on the number of ABC plans each care partner writes on the Orbit weekly survey and the STELLA-R website.

    Time frame: Week 1, Week 8

  5. Emotional and Physical Strain

    The Orbit weekly survey will measure emotional and physical strain for caregivers.

    Time frame: Weekly for 6 months

  6. Healthcare Use

    The Orbit weekly survey will measure service use and medication use for behavioral symptoms.

    Time frame: Weekly for 6 months

  7. Zarit Burden Interview

    The Orbit weekly survey will include the Zarit Burden Interview, a 4-item caregiver report measuring care partner burden. This measure is a 5-point Likert scale with a range of 0 (never) to 4 (nearly always) with higher scores meaning greater burden.

    Time frame: Weekly for 6 months

  8. The Neuropsychiatric Inventory (NPI-Q)

    The NPI-Q with Caregiver Self-Efficacy Scale evaluates 12 behavioral disturbances in dementia. Each domain captures severity of BPSD and caregiver self-efficacy. Severity is rated 1 (mild) to 3 (severe) and self-efficacy is reverse scored from 4 (not at all confident) to 1 (very confident). This measure assesses self-efficacy in addressing specific behavioral symptoms.

    Time frame: Week 1, Week 8, Week 16, Week 24

  9. Placement Plan Scale

    1-item Likert scale assessment of plans for placement of family member with dementia. Care partners will rate their likelihood of moving their family member with dementia to another living arrangement from 1 (not at all likely) to 5 (very likely).

    Time frame: Week 1, Week 8, Week 16, Week 24

  10. Use of Professional Services

    A 7-item binary assessment of professional services used to address their family member with dementia's needs in the past 2 months. Care partners will answer Yes or No to using a: dietitian, elder care attorney, occupational therapist, physical therapist, psychologist, social worker, speech therapist, and healthcare professional.

    Time frame: Week 1, Week 8, Week 16, Week 24

  11. Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)

    A 12-item assessment measuring mindfulness, distress, well-being, emotion-regulation, and problem-solving approaches. A Likert scale ranging from 1 (rarely/not at all) to 4 (almost always) with reverse scoring on items 2, 6 and 7.

    Time frame: Week 1, Week 24

  12. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if one is available) that assesses self-rated sleep quality and disturbances over a 1-month time interval. Only self-rated questions are included in scoring. The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. A score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The seven component scores are then added to yield one "global" score, with a range of 0-21 points. "0" indicating no difficulty and "21" indicating severe difficulties in all areas.

    Time frame: Week 1, Week 24

  13. ABC Plans

    A 1-item measure to assess total quantity of ABC plans created. Options are 1 (1-3), 2 (4-6), 3 (7-9) or 4 (10 or more). Experimental group completes this measure on weeks 8, 16 and 24. Wait-list control group completes this measure on weeks 16 and 24.

    Time frame: Week 8, Week 16, Week 24

07

Study locations

1 of 1 sites recruiting
  • Oregon Health & Science University, Layton Aging and Alzheimer's Disease Research Center
    Portland, Oregon 97239, United States
    Recruiting
    • Allison Lindauer, PhD · Contactlindauer@ohsu.edu · 503-494-6976
    • Allison Lindauer, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified IPD will be available upon request to our Alzheimer's Disease Research Center.

Supporting information: Study protocol

Time frame: Once data is available, it will be available indefinitely.

Access criteria: Requests need to be made to the PI at the Oregon Alzheimer's Disease Research Center (OARDC). A short data request form will need to be submitted.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 285 non-industry interventional studies with no phase under Caregiver Burden, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 28 months is above that.

Counting every sponsor, half of 294 studies reached it within 16 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 14, 2024
StartActual
Jul 2, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06460012
Collaborators
The Hart Family Foundation
Responsible party
Allison Lindauer (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Jun 14, 2024
Start date
Jul 2, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 23, 2025

Study contacts

Allison Lindauer, PhD
Contact
lindauer@ohsu.edu
(503) 449-8151
Christina Zonker, BA
Contact
zonkerc@ohsu.edu
(503) 816-8310
Allison Lindauer, PhD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion